Literature DB >> 8701939

Changes in blood coagulation during and following cardiopulmonary bypass: lack of correlation with clinical bleeding.

A B Gelb1, R I Roth, J Levin, M J London, R A Noall, W W Hauck, M Cloutier, E Verrier, D T Mangano.   

Abstract

Although previous studies have documented a wide variety of derangements in laboratory measurements of blood coagulation and platelets during cardiopulmonary bypass, limited data are available concerning the magnitude of these changes and any association with excessive bleeding. To determine whether abnormalities in commonly available laboratory tests for the evaluation of coagulation, fibrinolysis and hemostasis correlate with postoperative blood loss and transfusion requirements as measures of clinical outcome, 47 consecutive patients undergoing coronary artery bypass grafting with hypothermic cardiopulmonary bypass (CPB) were studied prospectively at 12 time points before, during, and following CPB. Routine blood coagulation tests, coagulation factor levels (fibrinogen, V, VII, VIII, and IX) and fibrinolysis (FDP) became abnormal within 15 minutes after patients were placed on CPB, remained abnormal for the duration of CPB, and recovered at varying rates after discontinuation of CPB. Mean factor V levels declined by the greatest percentage, to 15% of normal, followed by factor VIII which decreased to 30%. Platelet counts declined to below 100 x 10(9)/L after the initiation of CPB and remained low in the postoperative period. Twenty-eight percent of patients had mediastinal output > or = 100 mL per hour during the immediate postoperative period, and were considered to be "bleeders." There were no clinically relevant differences in any of the laboratory measurements between patients with normal postoperative blood loss and those defined as bleeders. Thus, the absence of significant correlations between various laboratory measurements of hemostasis and actual postoperative bleeding indicates that these laboratory derangements are transient, are not predictive of clinically important hemostatic abnormalities, and should not be used in isolation to guide the use of blood components in these patients. Furthermore, although bleeders received more blood components, there was surprisingly little effect on the coagulation factor levels measured.

Entities:  

Mesh:

Year:  1996        PMID: 8701939     DOI: 10.1093/ajcp/106.1.87

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

Review 1.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

Review 2.  Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass.

Authors:  Maryam Yavari; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2008-01-23       Impact factor: 2.300

3.  Blood Type O is not associated with increased blood loss in extensive spine surgery.

Authors:  Ryu Komatsu; Jarrod E Dalton; Michael Ghobrial; Alexander Y Fu; Jae H Lee; Cameron Egan; Daniel I Sessler; Yusuke Kasuya; Alparslan Turan
Journal:  J Clin Anesth       Date:  2014-08-27       Impact factor: 9.452

Review 4.  Modified ultrafiltration during cardiopulmonary bypass and postoperative course of pediatric cardiac surgery.

Authors:  Mohsen Ziyaeifard; Azin Alizadehasl; Gholamreza Massoumi
Journal:  Res Cardiovasc Med       Date:  2014-04-01

5.  Delayed gastric emptying in critical illness: is enhanced enterogastric inhibition with cholecystokinin and peptide YY involved?

Authors:  Andrew J W Samis
Journal:  Crit Care Med       Date:  2008-05       Impact factor: 7.598

Review 6.  Clinical application of viscoelastic point-of-care tests of coagulation-shifting paradigms.

Authors:  Soumya Sankar Nath; Chandra Kant Pandey; Sumit Kumar
Journal:  Ann Card Anaesth       Date:  2022 Jan-Mar

7.  Role of Using a Thromboelastometry-Based Protocol for Transfusion Management in Combined Coronary Artery Bypass Grafting and Valve Surgery: A Randomized Clinical Trail.

Authors:  Elham Khalaf-Adeli; Ali Akbar Pourfathollah; Fereidoon Noohi; Alireza Alizadeh-Ghavidel; Hooman Bakhshandeh-Abkenar; Roshanak Shamriz; Seyed Mostafa Alavi
Journal:  Indian J Hematol Blood Transfus       Date:  2020-11-09       Impact factor: 0.915

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.